Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 3/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.39 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | MLYCD | O95822 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL169273 | 0.90 | PDK2 (0.41) | PDK2ESR1ESR2ABHD6CREBBP | |
| SCHEMBL3528315 | 0.89 | NOTUM (0.43) | PDK2CREBBPEP300NPC1RAB9A | |
| SCHEMBL3527784 | 0.85 | CDK4 (0.44) | NPC1RAB9ASMN1; SMN2NAMPT | |
| SCHEMBL3529114 | 0.83 | ESR1 (0.44) | ESR1ESR2ABHD6CREBBPEP300 | |
| SCHEMBL169287 | 0.78 | NOTUM (0.42) | PDK2NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL16104413 | 0.76 | RAB9A (0.42) | PDK2NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL2129261 | 0.75 | ITGB2 (0.42) | SMN1; SMN2NAMPT | |
| SCHEMBL3533607 | 0.74 | KMT2A (0.42) | PDK2NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL13076550 | 0.74 | TMPRSS2 (0.46) | ESR1ESR2NPC1RAB9AKMT2A | |
| SCHEMBL3434989 | 0.73 | NAMPT (0.45) | ESR1ESR2NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101115-A1 | Compounds For Inducing Cellular Apoptosis | QUEEN MARY AND WESTFIELD COLLEGE (GB) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101115-A1 | Compounds For Inducing Cellular Apoptosis | BAD, BAX, CASP3 | PDK2 437/4885ESR1 3474/4885ESR2 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.